Literature DB >> 22267754

Tuberculosis: cost of illness in Germany.

Roland Diel1, Stefan Rutz, Stefanie Castell, Tom Schaberg.   

Abstract

4,444 new cases of tuberculosis (TB) were reported in Germany in 2009; of those, the proportion of multidrug-resistant (MDR)-TB cases increased to 2.1% (63 cases). On the basis of the therapy guidelines of the German Central Committee against Tuberculosis and the new World Health Organization guidelines, this study estimates the mean direct outpatient and combined in- and outpatient costs of TB, together with other attributable costs of the disease on the basis of the most recent German official health statistics and scientific literature. According to this, the mean outpatient costs (rounded) per case were €1,197 (adults) and €1,006 (children) for standard therapy, but €36,543 for treatment of MDR-TB. The mean combined in-patient/outpatient costs were €7,364 (adults) and €7,300 (children), respectively; the combined costs for treatment of MDR-TB amounted to €52,259. Including MDR-TB cases the mean costs of treatment per TB case were €7,931. These are joined by the mean costs due to loss of productivity (€2,313), costs per case for rehabilitation (€74) and contact tracing (€922), adding up to €11,240. When considering the probability of increasing numbers of MDR-TB cases in the near future, TB is still a disease of significant economic impact in Germany.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22267754     DOI: 10.1183/09031936.00204611

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  30 in total

1.  Cost-effectiveness analysis of interventions for tuberculosis control: DALYs versus QALYs.

Authors:  R Diel; N Lampenius
Journal:  Pharmacoeconomics       Date:  2014-07       Impact factor: 4.981

Review 2.  Delamanid and bedaquiline to treat multidrug-resistant and extensively drug-resistant tuberculosis in children: a systematic review.

Authors:  Lia D'Ambrosio; Rosella Centis; Simon Tiberi; Marina Tadolini; Margareth Dalcolmo; Adrian Rendon; Susanna Esposito; Giovanni Battista Migliori
Journal:  J Thorac Dis       Date:  2017-07       Impact factor: 2.895

Review 3.  Targeting multidrug-resistant tuberculosis (MDR-TB) by therapeutic vaccines.

Authors:  Satria A Prabowo; Matthias I Gröschel; Ed D L Schmidt; Alena Skrahina; Traian Mihaescu; Serap Hastürk; Rotislav Mitrofanov; Edita Pimkina; Ildikó Visontai; Bouke de Jong; John L Stanford; Père-Joan Cardona; Stefan H E Kaufmann; Tjip S van der Werf
Journal:  Med Microbiol Immunol       Date:  2012-11-10       Impact factor: 3.402

Review 4.  [Modern antituberculosis treatment].

Authors:  T Schaberg; T Bauer; R Loddenkemper
Journal:  Internist (Berl)       Date:  2013-05       Impact factor: 0.743

5.  Characteristics and costs of multidrug-resistant tuberculosis in-patient care in the United States, 2005-2007.

Authors:  S M Marks; Y Hirsch-Moverman; K Salcedo; E A Graviss; P Oh; B Seaworth; J Flood; L Armstrong; L Armitige; S Mase
Journal:  Int J Tuberc Lung Dis       Date:  2016-04       Impact factor: 2.373

6.  Barriers and facilitators to early access of bedaquiline and delamanid for MDR-TB: a mixed-methods study.

Authors:  C A Rodriguez; M B Brooks; L Guglielmetti; C Hewison; M F Jachym; E Lessem; F Varaine; C D Mitnick
Journal:  Public Health Action       Date:  2019-03-21

7.  Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis.

Authors:  Vija Skripconoka; Manfred Danilovits; Lea Pehme; Tarmo Tomson; Girts Skenders; Tiina Kummik; Andra Cirule; Vaira Leimane; Anu Kurve; Klavdia Levina; Lawrence J Geiter; Davide Manissero; Charles D Wells
Journal:  Eur Respir J       Date:  2012-09-27       Impact factor: 16.671

Review 8.  Costs to Health Services and the Patient of Treating Tuberculosis: A Systematic Literature Review.

Authors:  Yoko V Laurence; Ulla K Griffiths; Anna Vassall
Journal:  Pharmacoeconomics       Date:  2015-09       Impact factor: 4.981

9.  Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement.

Authors:  Christoph Lange; Ibrahim Abubakar; Jan-Willem C Alffenaar; Graham Bothamley; Jose A Caminero; Anna Cristina C Carvalho; Kwok-Chiu Chang; Luigi Codecasa; Ana Correia; Valeriu Crudu; Peter Davies; Martin Dedicoat; Francis Drobniewski; Raquel Duarte; Cordula Ehlers; Connie Erkens; Delia Goletti; Gunar Günther; Elmira Ibraim; Beate Kampmann; Liga Kuksa; Wiel de Lange; Frank van Leth; Jan van Lunzen; Alberto Matteelli; Dick Menzies; Ignacio Monedero; Elvira Richter; Sabine Rüsch-Gerdes; Andreas Sandgren; Anna Scardigli; Alena Skrahina; Enrico Tortoli; Grigory Volchenkov; Dirk Wagner; Marieke J van der Werf; Bhanu Williams; Wing-Wai Yew; Jean-Pierre Zellweger; Daniela Maria Cirillo
Journal:  Eur Respir J       Date:  2014-03-23       Impact factor: 16.671

10.  Latent Tuberculosis Infection among Health Workers in Germany-A Retrospective Study on Progression Risk and Use of Preventive Therapy.

Authors:  Nika Zielinski; Johanna Stranzinger; Hajo Zeeb; Jan Felix Kersten; Albert Nienhaus
Journal:  Int J Environ Res Public Health       Date:  2021-07-01       Impact factor: 3.390

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.